Last reviewed · How we verify

NCT04829357

Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

Recruiting now Last updated 13 April 2026
What this trial tests

trial testing Intervention in Stress Urinary Incontinence in 195 participants. Currently enrolling.

Timeline
9 September 2021
Primary endpoint
30 September 2036
27 February 2037

Quick facts

Lead sponsorEthicon, Inc.
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment195
Start date9 September 2021
Primary completion30 September 2036
Estimated completion27 February 2037
Sites4 locations across Switzerland, Italy, United States

Drugs / interventions tested

Conditions studied

Sponsor

Ethicon, Inc. — full company profile →

Who can join

21 and older, female only, with Stress Urinary Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Stress Urinary Incontinence

Currently open trials in the same condition.

Other Ethicon, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04829357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing